Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB

Biochemical Pharmacology

Volumn 80, Issue 9, 2010, Pages 1365-1372

  Deckmann, Klaus ^a   Rörsch, Florian ^a   Steri, Ramona ^a   Schubert Zsilavecz, Manfred ^a   Geisslinger, Gerd ^a   Grösch, Sabine ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

COX inhibitor; Dimethylcelecoxib; EGR1; MPGES 1; NF B

Indexed keywords

CELECOXIB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIMETHYLCELECOXIB; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROSTAGLANDIN E SYNTHASE 1; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,5-DIMETHYLCELECOXIB; CREB1 PROTEIN, HUMAN; EGR1 PROTEIN, HUMAN; ISOMERASE; PROSTAGLANDIN E SYNTHASE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; BINDING SITE; CELL STIMULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; GENETICS; HELA CELL LINE; PHYSIOLOGY; PROMOTER REGION;

BINDING SITES; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EARLY GROWTH RESPONSE PROTEIN 1; HELA CELLS; HUMANS; INTERLEUKIN-1BETA; INTRAMOLECULAR OXIDOREDUCTASES; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PYRAZOLES; SP1 TRANSCRIPTION FACTOR; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956650530     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.032     Document Type: Article

References (27)

1. Wobst I., Schiffmann S., Birod K., Maier T.J., Schmidt R., Angioni C., et al. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem Pharmacol 2008, 76:62-69.
2. Murakami M., Naraba H., Tanioka T., Semmyo N., Nakatani Y., Kojima F., et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792.
3. Murakami M., Nakashima K., Kamei D., Masuda S., Ishikawa Y., Ishii T., et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003, 278:37937-37947.
4. Koeberle A., Rossi A., Zettl H., Pergola C., Dehm F., Bauer J., et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Pharmacol Exp Ther 2010, 332:840-848.
5. Rorsch F., Wobst I., Zettl H., Schubert-Zsilavecz M., Grosch S., Geisslinger G., et al. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J Med Chem 2010, 53:911-915.
6. Guerrero M.D., Aquino M., Bruno I., Riccio R., Terencio M.C., Paya M. Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression. Eur J Pharmacol 2009, 620:112-119.
7. Forsberg L., Leeb L., Thoren S., Morgenstern R., Jakobsson P. Human glutathione dependent prostaglandin E synthase: gene structure and regulation. FEBS Lett 2000, 471:78-82.
8. Ekstrom L., Lyrenas L., Jakobsson P.J., Morgenstern R., Kelner M.J. Basal expression of the human MAPEG members microsomal glutathione transferase 1 and prostaglandin E synthase genes is mediated by Sp1 and Sp3. Biochim Biophys Acta 2003, 1627:79-84.
9. Naraba H., Yokoyama C., Tago N., Murakami M., Kudo I., Fueki M., et al. Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem 2002, 277:28601-28608.
10. Catley M.C., Chivers J.E., Cambridge L.M., Holden N., Slater D.M., Staples K.J., et al. IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett 2003, 547:75-79.
11. Fahmi H. mPGES-1 as a novel target for arthritis. Curr Opin Rheumatol 2004, 16:623-627.
12. Brautigam L., Nefflen J.U., Geisslinger G. Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. J Chromatogr B Anal Technol Biomed Life Sci 2003, 788:309-315.
13. Franzen R., Pautz A., Brautigam L., Geisslinger G., Pfeilschifter J., Huwiler A. Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells. J Biol Chem 2001, 276:35382-35389.
14. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004, 67:1469-1478.
15. Nubel T., Dippold W., Kleinert H., Kaina B., Fritz G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 2004, 18:140-142.
16. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002, 94:585-591.
17. Schonthal A.H. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 2006, 20:E21.
18. Monneret G., Boumiza R., Gravel S., Cossette C., Bienvenu J., Rokach J., et al. Effects of prostaglandin D(2) and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils. J Pharmacol Exp Ther 2005, 312:627-634.
19. Subbaramaiah K., Yoshimatsu K., Scherl E., Das K.M., Glazier K.D., Golijanin D., et al. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 2004, 279:12647-12658.
20. Chabane N., Li X., Fahmi H. HDAC4 contributes to IL-1-induced mPGES-1 expression in human synovial fibroblasts through up-regulation of Egr-1 transcriptional activity. J Cell Biochem 2009, 106:453-463.
21. Aicher W.K., Sakamoto K.M., Hack A., Eibel H. Analysis of functional elements in the human Egr-1 gene promoter. Rheumatol Int 1999, 18:207-214.
22. Wang B., Chen J., Santiago F.S., Janes M., Kavurma M.M., Chong B.H., et al. Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. Arterioscler Thromb Vasc Biol 2010, 30:536-545.
23. Kardosh A., Soriano N., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005, 106:4330-4338.
24. Wan F., Lenardo M.J. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res 2010, 20:24-33.
25. Mendez M., LaPointe M.C. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003, 42:844-850.
26. Ulrich S., Loitsch S.M., Rau O., von Knethen A., Brune B., Schubert-Zsilavecz M., et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 2006, 66:7348-7354.
27. Okada M., Yan S.F., Pinsky D.J. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 2002, 16:1861-1868.